Original Report

Difference in the timing of cessation of palliative chemotherapy between patients with incurable cancer receiving therapy only in a local hospital and those transitioned from a tertiary medical center to a local hospital


 

Background It is important to know when to decide to end palliative chemotherapy (PC) for the quality of life of patients. However, there is currently no clear agreement on when to terminate PC.
Objectives To determine whether the difference of the period between the completion of PC and death affects patients’ trajectory of supportive care near end of life.
Methods This retrospective study included 52 adult patients with incurable cancer who had received PC and who were referred to our palliative care team and died in our local hospital between July 2011 and June 2014. Group A comprised patients who received anticancer therapy such as surgery and PC only in our hospital and eventually died there. Group B comprised patients who were transitioned to our hospital from tertiary medical centers after cessation of PC.
Results 17 of 22 patients (77%) in Group A conveyed the intention of continuing PC in the first interview with a physician of the palliative care team, whereas 4 of 30 patients (13%) in Group B conveyed a similar intention. The patients in Group B stopped PC a median of 43 days earlier than did the patients in Group A (P < .0001).
Conclusions These data showed that more patients in Group A wanted to continue PC and had a shorter interval between last PC and death. Change in the hospital where the patients are given supportive care might contribute to the cessation of futile PC at an appropriate time.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

NCCN unveils 'Evidence Blocks' to facilitate treatment discussions
MDedge Hematology and Oncology
Dexamethasone reduces radiation therapy–induced pain flare
MDedge Hematology and Oncology
FDA finds long-term clopidogrel does not increase death or cancer risks
MDedge Hematology and Oncology
Survivors of childhood cancers at increased risk for autoimmune diseases
MDedge Hematology and Oncology
Suicide rate high in patients with head and neck cancer
MDedge Hematology and Oncology
ACS: Watchful waiting for some rectal cancers almost ready for ‘prime time’
MDedge Hematology and Oncology
Balancing clinical and supportive care at every step of the disease continuum
MDedge Hematology and Oncology
A modified olanzapine regimen for the prevention of chemotherapy-induced nausea and vomiting
MDedge Hematology and Oncology
Caregivers’ attitudes toward promoting exercise among patients with late-stage lung cancer
MDedge Hematology and Oncology
Impact of inpatient radiation on length of stay and health care costs
MDedge Hematology and Oncology